Statistics

Total Visits

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials79

Select a period of time:

Number of views in the range

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials31

Views

Views
July 202519
August 20251
September 20255
October 20252
November 20252
December 20252
January 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil11
United States7
United Kingdom3
Germany2
Austria1
Costa Rica1
Ecuador1
Ethiopia1
Mexico1
Paraguay1
 

Top cities views

Views
Frankfurt am Main2
São Paulo2
Dallas2
Adana1
Addis Ababa1
Ashburn1
Asunción1
Brasília1
Dourados1
Durban1